Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 480

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study

Kwok, Raymond, Choi, Kai Chow, Wong, Grace Lai-Hung, Zhang, Yuying, Chan, Henry Lik-Yuen, Luk, Andrea On-Yan, Shu, Sally She-Ting, Chan, Anthony Wing-Hung, Yeung, Ming-Wai, Chan, Juliana Chung-Ngor, Kong, Alice Pik-Shan, Wong, Vincent Wai-Sun·2016·Gut

Abstract

Objective: Type 2 diabetes is an important risk factor for non-alcoholic fatty liver disease (NAFLD), but current guidelines provide conflicting recommendations on whether diabetic patients should be screened for NAFLD. We therefore studied the strategy of screening diabetic patients by FibroScan. Design: Liver fat and fibrosis were assessed by controlled attenuation parameter (CAP) and liver stiffness measurements (LSM) by FibroScan at a diabetic centre for patients from primary care and hospital clinics. Probe-specific LSM cut-offs were used to detect advanced fibrosis. Results: Of 1918 patients examined, 1799 (93.8%) had valid CAP and 1884 (98.2%) had reliable LSM (1770 with the M probe and 114 with the XL probe). The proportion of patients with increased CAP and LSM was 72.8% (95% CI 70.7% to 74.8%) and 17.7% (95% CI 16.0% to 19.5%), respectively. By multivariable analysis, female gender, higher body mass index, triglycerides, fasting plasma glucose and alanine aminotransferase (ALT) and non-insulin use were associated with increased CAP. Longer duration of diabetes, higher body mass index, increased ALT and spot urine albumin:creatinine ratio and lower high-density lipoprotein-cholesterol were associated with increased LSM. Ninety-four patients (80% had increased LSM) underwent liver biopsy: 56% had steatohepatitis and 50% had F3-4 disease. Conclusions: Diabetic patients have a high prevalence of NAFLD and advanced fibrosis. Those with obesity and dyslipidaemia are at particularly high risk and may be the target for liver assessment. Our data support screening for NAFLD and/or advanced fibrosis in patients with type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2015-309265

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 480

Metadata

Authors
Kwok, R., Choi, K. C., Wong, G. L.-H., Zhang, Y., Chan, H. L.-Y., Luk, A. O.-Y., Shu, S. S.-T., Chan, A. W.-H., Yeung, M.-W., Chan, J. C.-N., Kong, A. P.-S., & Wong, V. W.-S.
Venue
Gut
Publisher
BMJ
Published
2015-04-14
Volume
65
Issue
8
Pages
1359-1368
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2039933259
Cited by
480
References
40
FWCI
28.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. https://app.cochat.ai/papers/10.1136/gutjnl-2015-309265
The paper
Kwok, R., Choi, K. C., Wong, G. L.-H., Zhang, Y., Chan, H. L.-Y., Luk, A. O.-Y., Shu, S. S.-T., Chan, A. W.-H., Yeung, M.-W., Chan, J. C.-N., Kong, A. P.-S., & Wong, V. W.-S. (2016). Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. https://doi.org/10.1136/gutjnl-2015-309265

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.